A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study

安慰剂 医学 置信区间 随机对照试验 偏头痛 临床试验 麻醉 内科学 物理疗法 病理 替代医学
作者
Jeffrey D. Sharon,Roseanne Krauter,Ricky Chae,Adam Gardi,Maxwell Hum,Isabel Elaine Allen,Morris Levin
出处
期刊:Headache [Wiley]
卷期号:64 (10): 1264-1272 被引量:32
标识
DOI:10.1111/head.14835
摘要

OBJECTIVE: To study if galcanezumab is effective for vestibular migraine (VM). BACKGROUND: There are currently no placebo-controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene-related peptide-targeted monoclonal antibody for VM. METHODS: This was a single site, prospective, double-blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18-75 years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM-PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3 months of treatment with galcanezumab or placebo via subcutaneous injection with a pre-filled syringe, 240 mg the first month, and 120 mg for the second and third months. RESULTS: Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM-PATHI score was reduced 5.1 points (95% confidence interval [CI] -13.0 to 2.7) for placebo (N = 21), and 14.8 points (95% CI -23.0 to -6.5) for galcanezumab (N = 17), a difference of -9.6 (95% CI -20.7 to 1.5, p = 0.044). DHI dropped 8.3 points in the placebo arm (95% CI -15.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI -31.9 to -12.1), a difference of -13.7 (95% CI -20.4 to -8.5, p = 0.018). The count of DDDs per month dropped from 18 days (standard deviation [SD] 7.6) in the baseline month to 12.5 days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9 days (SD 7.9) in the baseline month to 6.6 days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of -5.7 days (95% CI -10.7 to -0.7, p = 0.026). No serious adverse events were observed. CONCLUSIONS: In this pilot study, galcanezumab was effective in treating VM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
bkagyin的应助被浅陌采纳,获得10
刚刚
刚刚
田様的应助被一叶知秋采纳,获得10
刚刚
陈天降低完成签到,获得积分10
1秒前
1秒前
大水桶发布了新的文献求助10
1秒前
咸鱼打滚完成签到,获得积分10
1秒前
xyc完成签到,获得积分10
3秒前
慕青的应助被鳗鱼水云采纳,获得10
3秒前
3秒前
LCFXR发布了新的文献求助10
4秒前
LL完成签到,获得积分10
4秒前
4秒前
micor发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
XialianWeng完成签到,获得积分10
5秒前
Hong发布了新的文献求助10
5秒前
zhawenchang发布了新的文献求助10
5秒前
xxy发布了新的文献求助10
6秒前
周舟发布了新的文献求助10
6秒前
laoying关注了科研通微信公众号
6秒前
第五彧轩发布了新的文献求助10
7秒前
苹果绝义完成签到,获得积分10
7秒前
7秒前
7秒前
小蘑菇的应助被魔幻雨梅采纳,获得10
7秒前
Bonnienuit发布了新的文献求助50
7秒前
科研通AI6.2的应助被kun采纳,获得10
7秒前
Dcientist完成签到,获得积分10
8秒前
Orange的应助被安详念蕾采纳,获得10
8秒前
8秒前
明天过后完成签到,获得积分10
9秒前
peng发布了新的文献求助10
9秒前
满意血茗完成签到,获得积分20
9秒前
Camellia完成签到,获得积分10
9秒前
10秒前
华仔的应助被132采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8154161
求助须知:如何正确求助?哪些是违规求助? 9550701
关于积分的说明 21700590
捐赠科研通 7743260
什么是DOI,文献DOI怎么找? 3425651
关于科研通互助平台的介绍 2550861
邀请新用户注册赠送积分活动 2469363